Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:AIMT Aimmune Therapeutics (AIMT) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Aimmune Therapeutics Stock (NASDAQ:AIMT) 30 days 90 days 365 days Advanced Chart Ad Porter & CompanyElon Musk has put himself in their crosshairsToday, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.I share with you in this special investigative documentary. Get Aimmune Therapeutics alerts:Sign Up Key Stats Today's Range$34.49▼$34.4950-Day Range$34.30▼$34.5952-Week Range$10.09▼$37.00VolumeN/AAverage Volume1.71 million shsMarket Capitalization$2.26 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.Read More… Elon Musk has put himself in their crosshairs (Ad)Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.I share with you in this special investigative documentary. Receive AIMT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AIMT Stock News HeadlinesAimtron Electronics Ltd (AIMT)November 14 at 3:06 PM | investing.comAimmune Therapeutics to Present New Data for PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp] at the EAACI Hybrid Congress 2022June 30, 2022 | finance.yahoo.comElon Musk has put himself in their crosshairsToday, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.November 14, 2024 | Porter & Company (Ad)Aimmune Therapeutics Presents New PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp] Data on Immunological Outcomes of Long-Term Daily Oral Immunotherapy at the EAACI PAAM Digital MeetingNovember 12, 2021 | financialpost.comAimmune Closes Enrolment in Phase III Peanut Allergy StudyOctober 26, 2021 | finance.yahoo.comAimmune’s PALISADE-ARC004 Longitudinal Study Showed PALFORZIA® Safety and Efficacy Increased Over Time in Patients with Peanut AllergyAugust 4, 2021 | ca.finance.yahoo.comSee More Headlines AIMT Stock Analysis - Frequently Asked Questions How were Aimmune Therapeutics' earnings last quarter? Aimmune Therapeutics, Inc. (NASDAQ:AIMT) posted its earnings results on Thursday, July, 30th. The biotechnology company reported ($1.06) EPS for the quarter, hitting analysts' consensus estimates of ($1.06). When did Aimmune Therapeutics IPO? Aimmune Therapeutics (AIMT) raised $124 million in an initial public offering on Thursday, August 6th 2015. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Credit Suisse and Piper Jaffray served as the underwriters for the IPO. What other stocks do shareholders of Aimmune Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aimmune Therapeutics investors own include Hawkins (HWKN), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Meta Platforms (META), Xtrackers California Municipal Bond ETF (CA) and Bristol-Myers Squibb (BMY). Company Calendar Last Earnings7/30/2020Today11/14/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:AIMT CUSIPN/A CIK1631650 Webwww.aimmune.com Phone650-614-5220FaxN/AEmployees228Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-248,500,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-164.99% Return on Assets-89.50% Debt Debt-to-Equity Ratio0.73 Current Ratio7.53 Quick Ratio7.40 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.66 per share Price / Book20.78Miscellaneous Outstanding Shares65,450,000Free FloatN/AMarket Cap$2.26 billion OptionableOptionable Beta1.76 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:AIMT) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThis small cap’s electric marine powertrain broke the world speed recordThe future of marine propulsion has arrived-powered by a $2 billion powerhouse. In collaboration with McLar...The Tomorrow Investor | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredThe next assassination attempt won’t be on TrumpPresident Trump is soon to be back in the White House. Unity has been restored to the U.S. But if you wa...Porter & Company | SponsoredElon Musk’s $30 Billion Trump Bet Pays Off—What’s Next?Elon Musk bet big on Trump's victory, and that gamble has already added over $30 billion to his net worth in a...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aimmune Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aimmune Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.